TNFRSF8 and non-Hodgkin lymphoma: Antigen-specific monoclonal antibodies (mAbs) are established as immunotherapeutic agents for the treatment of human malignancies such as non-Hodgkin lymphoma (NHL), CD30-positive lymphoma [1,2], EGFR-expressing advanced bowel cancer, metastatic colorectal carcinoma [3-6].